Skip to main content
Toggle navigation
FR
EN
Drupal
Main navigation EN
About Crossject
Who we are
Governance
R&D
Our technology
ZENEO®: needle-free technology
Products under development
Our supply chain
Therapeutic areas
Epileptic seizure
Acute adrenal crisis
Anaphylactic shock
Severe asthma crisis
Migraines and cluster headaches
Opioid overdose
Rheumatoid arthritis
Main navigation 2 EN
Finances
Profile
Analyst coverage
Financial releases
News
Our news
Press releases
Careers
Working at Crossject
Contact
Search
Search
Enter the terms you wish to search for.
Home
Finances
First-half 2020 results and business update
First-half 2020 results and business update
Image
Date de parution
2020/09/21
PDF du document
CP_2020_09_Crossject _Resultats semestriels 2020 vdef_ENG .pdf
199.15 KB
